These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 32526750)

  • 21. Immunotherapy in AL Amyloidosis.
    Zhang Y; Comenzo RL
    Curr Treat Options Oncol; 2022 Jul; 23(7):1059-1071. PubMed ID: 35635625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
    Rybinski B; Kocoglu M
    Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized Approach to Management of Light Chain Amyloidosis.
    Palladini G; Milani P
    J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AL amyloidosis: untangling new therapies.
    Bal S; Landau H
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):682-688. PubMed ID: 34889374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Review of AL amyloidosis: some practical recommendations.
    Al Hamed R; Bazarbachi AH; Bazarbachi A; Malard F; Harousseau JL; Mohty M
    Blood Cancer J; 2021 May; 11(5):97. PubMed ID: 34006856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solid Organ Transplantation in Amyloidosis.
    Theodorakakou F; Fotiou D; Dimopoulos MA; Kastritis E
    Acta Haematol; 2020; 143(4):352-364. PubMed ID: 32535598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
    Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of the elderly patient with AL amyloidosis.
    Nuvolone M; Milani P; Palladini G; Merlini G
    Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.
    Muchtar E; Dispenzieri A; Gertz MA; Kumar SK; Buadi FK; Leung N; Lacy MQ; Dingli D; Ailawadhi S; Bergsagel PL; Fonseca R; Hayman SR; Kapoor P; Grogan M; Abou Ezzeddine OF; Rosenthal JL; Mauermann M; Siddiqui M; Gonsalves WI; Kourelis TV; Larsen JT; Reeder CB; Warsame R; Go RS; Murray DL; McPhail ED; Dasari S; Jevremovic D; Kyle RA; Lin Y; Lust JA; Russell SJ; Hwa YL; Fonder AL; Hobbs MA; Rajkumar SV; Roy V; Sher T
    Mayo Clin Proc; 2021 Jun; 96(6):1546-1577. PubMed ID: 34088417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future directions in the clinical management of amyloid light-chain amyloidosis.
    Haider S; Ahmad N; Anaissie E; Driscoll JJ
    Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AL amyloidosis: advances in diagnostics and treatment.
    Ryšavá R
    Nephrol Dial Transplant; 2019 Sep; 34(9):1460-1466. PubMed ID: 30299492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic immunoglobulin light chain amyloidosis.
    Merlini G; Dispenzieri A; Sanchorawala V; Schönland SO; Palladini G; Hawkins PN; Gertz MA
    Nat Rev Dis Primers; 2018 Oct; 4(1):38. PubMed ID: 30361521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2020 Jul; 95(7):848-860. PubMed ID: 32267020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pharmacist's review of the treatment of systemic light chain amyloidosis.
    Hughes DM; Staron A; Sanchorawala V
    J Oncol Pharm Pract; 2021 Jan; 27(1):187-198. PubMed ID: 33028132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.